SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on December 21, 2007, reporting events occurring on December 20, 2007. The registrant is a Colorado-based biopharmaceutical company focused on research and development. Note: The request metadata referenced "Riot Platforms, Inc." and a 2007 date, but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock.
- Gross Proceeds: Approximately $18 million.
- Shares Issued: Approximately 2.5 million shares.
- Purchase Price: $7.25 per share.
- Placement Fee: 6% of gross proceeds.
- Expected Closing Date: On or about December 24, 2007.
Material Changes and Use of Proceeds
The filing discloses a material definitive agreement entered into with accredited existing and new investors. Net proceeds, after deducting the 6% placement fee and specified closing expenses, are designated for:
- Research and development.
- Product development.
- FDA approval related activities.
- Working capital and general corporate purposes.
The company has agreed to file a registration statement to register the shares within thirty days following the closing. The offering relies on Section 4(2) of the Securities Act of 1933 and Rule 506.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or detailed risk factors beyond the standard closing conditions for the transaction. The primary contingency is the satisfaction of customary closing conditions required to finalize the $18 million capital raise.
Key Facts for Investor Verification
- Verify the actual closing date of the transaction (expected December 24, 2007) and confirmation of fund receipt.
- Confirm the exact number of shares issued and the final net proceeds after the 6% fee and expenses.
- Monitor the filing of the registration statement for the shares within the required 30-day post-closing window.
- Review subsequent filings for updates on the allocation of funds toward FDA approval activities and product development milestones.